(NYSE American: ATNM) Makes Strong Green Statement In Pre-Market (Key Press Releases Here)

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is cooking this morning and just hit the top of my watchlist.

*Sponsored (NYSE American: ATNM) Makes Strong Green Statement In Pre-Market (Key Press Releases Here) March 25th Greetings, Friend! Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is cooking this morning and just hit the top of my watchlist. With an early green burst in pre-market, ATNM could be positioning itself to gain further attention as the bell approaches. A couple key points to note now: #1. The company announced this a little bit ago: Actinium Pharmaceuticals to Host KOL In-vestor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opp's Including Newly Initiated Actimab-A Solid Tumor Program #2. ATNM dropped significant news yesterday: Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities Time's ticking to consider (NYSE American: ATNM) for your watchlist. ----- Get ready for a game-changing report! This isn't just any ordinary update - it's a deep dive into a company that's making waves in the pharmaceutical industry. Here's why you need to know about the company: Innovative Cancer Treatments: Learn about cutting-edge therapies that could revolutionize how we approach certain types of cancer. Potential Market Disruption: Discover how this company's unique approach could shake up the entire pharmaceutical landscape. Impressive Clinical Trial Results: Get the inside scoop on recent trial outcomes that could generate serious buzz. Strategic Partnerships: Uncover the powerful alliances this company has formed to accelerate its growth and impact. Intellectual Property Portfolio: Explore the robust patent protection surrounding their groundbreaking technologies. Analyst Target: At least one analyst is suggesting this profile to have over 200% potential upside from its closing valuation Monday. All this and more is why you should consider this NYSE American profile for your radar: Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents a potential multi-Bn-dollar addressable market. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for the U.S. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium Pharmaceuticals, Inc. Pipeline Grab Sources And More Here: ATNM Website. ----- 6 Immediate Potential Catalysts Could Paint Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) With A Breakout Target... #1. Monday Afternoon's Major News Announcement: With an afternoon press release Monday, potentially under-the-radar going into Tuesday, Actinium Pharmaceuticals has secured a supply agreement with Eckert & Ziegler for Actinium-225, a critical radioisotope, to support the development of its lead product Actimab-A and other candidates for cancer treatment in U.S. and international clinical trials. #2. Growing Chart Momentum: Since the beginning of March, ATNM has climbed more than 50% from a $1.02+ low to a $1.59 high. With this move, ATNM has pushed above 4 key technical chart levels. If potential support grows at those levels, it could help ATNM maintain its recent green stretch this month. #3. A Strong Analyst Target: Stephens, Inc. analyst, Sudan Loganathan, Ph.D., maintains an "Overweight" rating with a $5.00 target. From it's 4:00PM EST closing valuation on Monday, ATNM may have over 200% potential upside to this target. #4. A Highly Promising Research Collab: Actinium Pharmaceuticals has entered into a research collaboration with Memorial Sloan Kettering Cancer Center to expand the potential of Actimab-A, their lead radiotherapeutic for acute myeloid leukemia (AML). The collaboration aims to study Actimab-A in combination with targeted therapies and assess its activity on patient-derived AML samples, with the goal of addressing unmet needs in myeloid malignancies and potentially improving patient outcomes. #5. A Clinical Trial Announcement: Actinium Pharmaceuticals has announced a new clinical trial program combining Actimab-A with PD-1 checkpoint inhibitors KEYTRUDA® and OPDIVO® for solid tumors, focusing on Head and Neck Squamous Cell Carcinoma (HNSCC) and Non-Small Cell Lung Cancer (NSCLC). The trials aim to improve patient outcomes by targeting Myeloid Derived Suppressor Cells (MDSCs) in the tumor microenvironment, with initial proof of concept clinical data expected in the second half of 2025. #6. Initiation Of Combination Frontline Trial: Actinium Pharmaceuticals has initiated a Phase 1/2 clinical trial combining Actimab-A with Venetoclax and Azacitidine for relapsed or refractory acute myeloid leukemia (AML) under a Cooperative Research and Development Agreement with the National Cancer Institute. The trial aims to evaluate safety, tolerability, and efficacy, leveraging Actimab-A's mutation-agnostic mechanism to improve treatment outcomes, with initial data expected in late 2025. ----- Coverage is officially initiated on Actinium Pharmaceuticals, Inc. (NYSE American: ATNM). I'll be in touch with updates. Be on the lookout. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 03/25/2025 and ending on 03/25/2025 to publicly disseminate information about (ATNM:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (ATNM:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/atnm/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice